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Medicine, Kyoto, 606-8507, Japan; Department of Urology (A.K.), Hyogo College of Medicine,
Nishinomiya, 663-8131, Japan; and Department of Cell Physiology (H.H.), Nagoya City University
Graduate School of Medical Sciences, Nagoya, 467-8601, Japan.
Acute bladder distension causes various morphologic and functional changes, in part through
altered gene expression. We aimed to investigate the physiologic role of PTHrP, which is up-
regulated inanacutebladderdistensionmodel in female rats. In the control Emptygroup,bladders
werekeptempty for 6hours, and in theDistensiongroup,bladderswerekeptdistended for 3hours
after an artificial storing-voiding cycle for 3 hours. In the Distention group bladder, up-regulation
of transcriptswas noted for 3 genes reported to be up-regulated by stretch in the cultured bladder
smooth muscle cells in vitro. Further transcriptome analysis by microarray identified PTHrP as the
22nd highest gene up-regulated in Distension group bladder, among more than 27 000 genes.
Localization of PTHrP and its functional receptor, PTH/PTHrP receptor 1 (PTH1R), were analyzed in the
untreated rat bladders and cultured bladder cells using real-time RT-PCR and immunoblotting, which
revealed thatPTH1RandPTHrPweremorepredominantly expressed in smoothmuscle than inurothe-
lium. Exogenous PTHrP peptide (1-34) increased intracellular cAMP level in cultured bladder smooth
muscle cells. In organbath study using bladder strips, the PTHrP peptide caused amarked reduction in
the amplitudeof spontaneous contractionbut causedonlymodest suppression for carbachol-induced
contraction. In in vivo functional study by cystometrogram, the PTHrP peptide decreased voiding
pressure and increased bladder compliance. Thus, PTHrP is a potent endogenous relaxant of bladder
contraction,andautocrineorparacrinemechanismofthePTHrP-PTH1Raxis isaphysiologicallyrelevant
pathway functioning in the bladder. (Endocrinology 154: 2058–2068, 2013)
Bladderdistension causedbybladderoutlet obstructionis a condition frequently encountered in urologic clin-
ics that causes various morphologic and functional
changes to thebladder, includingmatrix remodeling,mus-
cular hypertrophy, bladder decompensation, and bladder
overactivity (1–4). According to themyogenic bladder re-
modeling hypothesis, transcriptional changes in gene ex-
pression are involved in such changes (5), and we have
previously shown that collagen I/III and connexin 43 are
genes that affect myogenic changes after bladder outlet
obstruction (1, 6).
Adam and colleagues (7) performed comprehensive tran-
scriptome analysis on cultured bladder smooth muscle cells
(BSMCs) subjected to cyclic stretch to study the effect of
bladder distension on gene expression in vitro. Transcrip-
tional changes found in the in vitromodelwere subsequently
validated using an ex vivo bladder distensionmodel. Several
genes, including heparin-binding epidermal growth factor
(EGF)-like growth factor, cyclooxygenase2, and thrombo-
modulin, were found to be up-regulated in both the in vitro
and ex vivo studies, indicating that genetic changes in the
distended bladder are caused, at least in part, bymechanical
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stretch to smooth muscle cells. However, such comprehen-
sive transcriptional analysis has not yet been reported for in
vivo acute bladder distension, leaving the physiologic rele-
vance of the findings uncertain.
PTHrP was originally identified as a cause for hypercal-
cemia inparaneoplastic syndrome.BothPTHandPTHrPact
as ligands for PTH/PTHrP receptor 1 (PTH1R). PTH is ex-
pressed solely in the parathyroid, whereas PTHrP is ex-
pressed in most tissues in the body. Whereas PTH func-
tions as an endocrine hormone with bone and kidneys as
the main target organs, PTHrP is considered to be an au-
tocrine or paracrine ligand for PTH1R in various organs
with diverse functions such as bone growth regulation,
calcium transport, mammary gland development, tooth
eruption, and smooth muscle relaxation (8-10). There are
two types of PTH receptor, PTH1R and PTH2R, but
PTH2R is known to be activated solely by PTHand not by
PTHrP (11). Thus, PTH1R is considered to be the only
functional target of PTHrP in these organs. PTHrP was
found tobeup-regulatedbybladder distension and stretch
of smooth muscle cells and was identified as a relaxant of
bladder smooth muscle in 2 early reports (12, 13). How-
ever, its effect on carbachol (CCh)-induced muscle con-
traction. as shown in these initial reports, was only mod-
est, and no further functional studies have been
undertaken since. In the initial studies, the expression and
localization of PTH1R in the bladder, the downstream
pathway of PTH1R, and the in vivo effect of PTHrP in the
bladder were not investigated (13). In short, the study on
PTHrP as a functional molecule in the bladder has been
interrupted, except for a short report on its immunohis-
tochemical localization without functional analysis (14).
In the present report, PTHrP is rediscovered as a highly
up-regulated molecule in a rat bladder acute distension
model in vivo, using microarray analysis. Thus, we sub-
sequently reinvestigate the physiologic role of PTHrP in
the bladder as a candidate gene for functional changes
after acute bladder distension and demonstrate a relevant
physiologic effect of PTHrP on spontaneous contraction




Eight-week-old female SpragueDawley rats (180–220g, SLC
Japan, Hamamatsu, Japan) were used for all experiments in
this study. Rats were housed at constant room temperature
with a 14-hour light (7:00 AM to 9:00 PM), 10-hour dark (9:00
PM to 7:00 AM) cycle. Food and water were available ad libitum.
Rats were treated according to guidelines (15). All animal ex-
periments were approved by the Kyoto University and Nagoya
City University animal experiment committees, and all animals
used in this study were treated according to The Guidelines for
Animal Experimentation of the Experimental Animal Center of
Kyoto University and Nagoya City University
Cell culture
BSMCsandurothelial cells (UCs)were isolated fromrat blad-
ders using a previously described procedure (1, 16, 17). After 2
passages, BSMCs were seeded at 105/2 mL in 6-well plates for
RNA and protein extraction and at 104/100L in 96-well plates
for cAMP-enzyme immunoassay (EIA) assays.
Rat bladder distension model
For the in vivo bladder distension model, rats were anesthe-
tized by sc urethane injection (1.2 g/kg). Saline was infused into
the urinary bladder through a transurethral catheter, and the
intravesical content was drained through the urethra around the
transurethral catheter. Rats were randomly divided into 3 groups:
in the Empty group, bladders were kept empty for 6 hours; in the
Storing-Voiding cycling group, bladderswere kept ona storing and
voiding cycle with continuous saline infusion (1mL/h) for 3 hours;
in the Distension group, bladders were kept on a storing-voiding
cycle as in the Storing-Voiding cycling group, after which the blad-
derswerekept distendedby clamping theurethra at the volume just
before voiding for anadditional 3hours (n4–5per group, Figure
1A).After the experiment described, ratswere humanely destroyed
bywithcervicaldislocation,andwholebladdertissueswereusedfor
extraction of RNA.
Because 3-hour distensionwas expected to be too short for pro-
tein expression, we used gradual distension model for protein re-
trieval, with a method described previously (12), and distension
time was extended to 6 hours. Six hours Empty group and 6 hours
Distension group were compared (n 2 for representative immu-
noblot, and n 6 for densitometry), and bilateral ureteral ligation
wasperformedintheEmptygroup,becauseurinedrainagefromthe
urethra outside the transurethral catheter was not reliable to keep
the bladder empty for an additional 3 hours. Shamoperations (lap-
arotomy and isolation of bilateral ureters) were performed in the
Distension group. Before closing the abdominal wall, 5 mL saline
was infused ip in each group. Retrieval of the bladder was done in
the same manner as described above.
Tissue separation for localization analyses
For localization analyses, untreated rat bladders were sepa-
rated to muscle layer and urothelium using ophthalmology scis-
sors. Each tissue has undergone RNA or protein extraction.
Real-time RT-PCR
Total RNA was extracted from bladder tissue or cells and
treatedwithDNase I usingRNeasyMini kits (QIAGEN,Hilden,
Germany) and RNase-Free DNase Sets (Qiagen), according to
the manufacturer’s protocols. cDNAwas synthesized from total
RNA using First-Strand cDNA Synthesis Kits (GE Healthcare,
Waukesha, Wisconsin). Real-time PCR was performed using
SYBRgreen PCRMasterMix (Life Technologies, Carlsbad,Cal-
ifornia) and recorded by 7300 Realtime PCR system (Life Tech-
nologies) (n 6). The thermal cycling conditions were 94°C for
15 s, 57°C for 15 s, and 72°C for 1min. Values were adjusted by
the expression levels of 18s rRNA. Primer sequences are shown
in Table 1.
doi: 10.1210/en.2012-2142 endo.endojournals.org 2059
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 19:03 For personal use only. No other uses without permission. . All rights reserved.
Affymetrix GeneChip array
Comprehensive gene expression analysis was performed for
total RNA isolated from the Empty and Distended rat bladders
(n  3 each) using the Affymetrix GeneChip Rat Gene 1.0 ST
Array containing probes for more than 27 000 well-annotated
genes. RNA concentration and purity were determined by mea-
surement of A260/A280 ratios with a NanoDrop ND-1000 Spec-
trophotometer (Thermo Fisher Scientific, Waltham, Massachu-
setts).RNAqualitywasassessedusingtheAgilent2100Bioanalyzer
(Agilent Technologies, Palo Alto, California). Aliquots of 100 ng
total RNA were used for each sample. Target labeling, array hy-
bridization, washing, and staining were performed as described in
the GeneChip Whole Transcript Sense Target Labeling manual
(http://www.affymetrix.com). Arrays were scanned using the Ge-
neChip Scanner 3000 7G (Affymetrix).
Data acquisition was performed with the GeneChip Com-
mand Console Software (AGCC). Data analysis was performed
with GeneSpring GX Version 11.5.1 (Agilent Technologies)
under the following conditions: summarization algorithm,
RMA16; confidence level, all; baseline options, do not perform
baseline transformation. In a total of 27 342 genes on the mi-
croarray, genes with more than 80% signal intensity (22 726
genes) were used for comprehensive analysis. Expression
changes between the Distension group and the Empty group
were calculated.
Immunoblotting
After washing with ice-cold PBS, rat bladder tissue or cells
were lysed in lysis buffer containing 50 mM Tris-HCl (pH 7.4),
1%TritonX-100, 150mMsodiumchlo-
ride, 2 mM EDTA, 1 mM EGTA, 0.2
mM sodium vanadate, 50 mM sodium
fluoride, 1mMdithiothreitol, and 1mM
phenylmethylsulfonyl fluoride supple-
mented with protease cocktail inhibitors
(Complete Mini; Roche, Mannheim,
Germany) for PTHrP, and in radioim-
mune precipitation assay buffer with
protease inhibitor (Nacalai Tesque,
Kyoto, Japan) for PTH1R. The extracts
were centrifuged at 13 000 g at 4°C for
20 minutes. Total cellular protein con-
centrationswere determined using a pro-
tein assay reagent (Bio-Rad Laborato-
ries, Inc.,Richmond,California). Protein
lysates (for PTHrP: 80 g, for PTH1R:
20 g) were subjected to SDS-PAGE us-
ing 15% gel for PTHrP, and 8% gel for
PTH1R, and transferred to polyvi-
nylidene difluoride membranes (Milli-
pore Corp, Bedford, Massachsetts).
Membranes were immunoblotted with
primary antibodies followed by horse-
radish peroxidase-conjugated secondary
antibodies and developed for reading by
enhanced chemiluminescence (Pierce
WesternBlotting Substrate Plus; Thermo
Scientific, Rockford, Illinois). Images
were acquired with the LAS-4000 imag-
ing system (Fujifilm Life Science, Tokyo,
Japan) (18, 19). Anti-PTHrP (PC-09,
Merck KGaA, Darmstadt, Germany; diluted at 1:100), anti-
PTH1R (PRB-630P; Covance Laboratories, Madison, Wiscon-
sin; diluted at 1:1000), anti--smooth muscle actin (SMA)
(ab5694, Abcam, Cambridge, UK; diluted at 1:10 000), anti-
cytokeratin 18 (C8541; Sigma Aldrich, St Louis, Missouri; di-
luted at 1:4000), and anti--actin (AC-15; ab6276 Abcam; di-
luted at 1:25000) were used as primary antibodies.
cAMP-EIA assay
BSMCs were seeded at 1.0  104 per well in 96-well plates
and incubated for 24 hours in DMEM (Invitrogen, Carlsbad,
California) supplemented with 10% fetal calf serum. The me-
dium was changed to serum-free DMEM 24 hours before the
assay. One hour before the assay, 10 nM PTHrP(1-34) amide
(4502-v, Peptide Institute, Osaka, Japan), an agonist of PTH1R,
or vehicle was added with 3-isobutyl-1-methylxanthine (I5879;
Sigma Aldrich; final concentration 0.1 mM). In addition, either
10 nM PTHrP(7-34) amide (4512-v; Peptide Institute), an an-
tagonist of PTHrP, or 10 mM 9-(tetrahydro-2-furanyl)-9H-pu-
rin-6-amine (SQ22536) was added for PTHrP treatment. Intra-
cellular cAMP concentrations were assayed using cAMP-EIA kit
(RPN225; GE HealthCare) (n  6) (20).
Organ bath study
Tissue preparations
A total of 30 rats without any treatment were anesthetized
with isoflurane inhalation and exsanguinated by decapitation.























































Figure 1. An in Vivo Acute Bladder Distention Model A, Schematic of the rat bladder acute
distension model. †, time of sacrifice; SV, storing-voiding. B, Characterization of the rat bladder
distention model. The distended rat bladder showed transcriptional changes similar to bladder
smooth muscle cells subjected to cyclic stretch, as previously reported. The value of the empty
group is set at 1 (n  6, P  .05). Cox2, cyclooxygenase 2; HB-EGF, heparin-binding EGF-like
growth factor; THBD, thrombomodulin.
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with the urothelial side facing up. The urothelial layer was dis-
sected away from the smoothmuscle layer using ophthalmology
scissors. After the sample was turned upside down, the outer
smooth muscle layer was removed, leaving the inner smooth
muscle layer for use in the study.
Isometric tension recordings
Silk threadswere tied around both ends of the smoothmuscle
strips (8–10mm long; 1–3mmwide). Preparationswere trans-
ferred to 2 mL organ baths and superfused with warmed (35°C)
physiologic salt solution (21) at a constant flow rate (2-3 mL/
min). One thread was fixed to the bottom of the organ bath,
while the other was connected to an isometric force transducer
connected to a bridge amplifier. Isometric tension changes were
digitizedusingaDigidata1200 interface (Axon Instruments, Inc,
Foster City, California) and stored on a personal computer for
later analysis.After 30minutes of incubationwithwarmedphys-
iologic salt solution, preparations were stretched appropriately
to exhibit spontaneous phasic contraction. Preparations were
then left to equilibrate for about 30–60 minutes until sponta-
neous phasic contraction became stable in both amplitude and
frequency.
Cystometrogram
For cystometrogram, a total of 32 rats without any treatment
were anesthetized with an sc injection of urethane (0.9 g/kg).
After laparotomy, the bladder was exposed and both ureters
were tied and cut. A polyethylene catheter (PE60; Clay-Adams,
Parsippany, New Jersey) with a needle was inserted into the
bladder dome and held in place with a purse-string suture. The
catheter was connected via a 3-way stopcock to a pressure trans-
ducer (DX-360; Nihon Kohden, Tokyo, Japan) for recording of
the intravesical pressure, and to a syringe pump (STC-521;
Terumo Corp., Tokyo, Japan) for infusion of saline into the
bladder. After checking for leaks, the bladder was emptied by
gently pushing the hypogastrium. In the same session, a needle
was inserted into one of the femoral veins for iv injection. Cys-
tometrogramwas carried out by filling the bladder with saline at
a rate of 6 mL/h to elicit repetitive voiding. Intravesical pressure
signals were conveyed to a carrier amplifier (AP-621G; Nihon
Kohden) and continuously recorded on a pen recorder (RJG-
4124; Nihon Kohden). After intercontraction interval and am-
plitudes of bladder contractions had stabilized, 10 g PTHrP(1-
34) amide in 180 L saline or saline only was administered iv.
Ten sequential micturition cycles were selected immediately be-
fore and after drug administration. Average intercontraction in-
tervals and pressure of bladder before and after the filling phase
and at the peak of contraction were measured to calculate max-
imum intravesical pressure and compliance during filling phase.
The percentages of change before and after drug administration
were calculated (22, 23).
Statistical analysis
Data are expressed as mean SEM.Microsoft Excel was used
for statistical analysis. Student’s t-tests and paired t-tests were per-
formed when appropriate. P .05 was accepted as significant.
Agents
PTHrP(1-34)amide (4205-v) and PTHrP(7-34)amide
(4215-v) were obtained from Peptide Institute (Osaka, Japan).
Cch, forskolin, 8-bromo-cAMP, and SQ22536(S-153) were ob-
tained from Sigma-Aldrich (St Louis, Missouri). H-89 was ob-
tained from Nacalai Tesque (Kyoto, Japan).
Results
Creation and characterization of the model
To investigate transcriptional changes during acute
bladder distension, we used a rat bladder acute distension
model (Figure 1A). To compare this in vivo model with
BSMCs under cyclic stretch in vitro, we investigated the
expression levels of 3 genes reported to be up-regulated in
stretched BSMCs: cyclooxygenase 2, heparin-binding-
EGF, and thrombomodulin (7). Real-time RT-PCR
showed that all 3 selected genes were also significantly
up-regulated after bladder distension in our in vivomodel
(Figure 1B), demonstrating that genetic changes in this in
vivomodel reflect the effects of stretch on smoothmuscle.
Affymetrix GeneChip Array
Wenextperformedcomprehensive transcriptomeanal-
ysis of the animal model. In a total of 27 342 genes on
microarray, 353 genes were significantly up-regulated
more than 2-fold by bladder distension, and 198 genes
were down-regulatedmore than 2-fold. The 30 geneswith
highest level of up-regulation are shown in Table 2. Fol-
lowing literature study of these genes, we focused on
Table 1. Real-time RT-PCR Primer Information.
Gene Primer Sequence (533)






















Cox2, cyclooxygenase 2; CK20, cytokeratin 20; F, forward, R, reverse;
HB-EGF, heparin-binding EGF-like growth factor; SM-MHC, smooth
muscle myosin heavy chain; THBD, thrombomodulin; UP3a,
uroplakin 3a.
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PTHrP (bold in Table 2, 22nd highest up-regulation; fold
change6.17;P .002) as a candidate of functional gene
associated with acute distension, because of incomplete
characterization done thus far for this molecule in the
bladder.
Expression study of PTH/PTH1R in the bladder
Up-regulation of PTHrP transcription after acute blad-
der distension suggested by Affymetrix GeneChip Array
was validated by real-time RT-PCR, with a 4.97  0.75-
fold up-regulation in theDistension group comparedwith
the Empty group (P  .001, Figure 2A). The increase in
PTHrP protein level was demonstrated by immunoblot-
ting of the tissues from the 6-hour Empty group and the
6-hour Distension group, and densitometry showed a sig-
nificant difference in PTHrP expression between the two
groups (P  .011, Figure 2B-1,2).
As the next step, the localization of PTHrP was inves-
tigated in bladder smooth muscle and urothelium. The
accuracy of separating the urothelium from the muscle
was validated by examining mRNA levels of 3 smooth
muscle markers (-SMA, smooth muscle myosin heavy
chain, and calponin) and 2 urothelial markers (uroplakin
3aandcytokeratin20), all ofwhich showeddistinct tissue-
specific localization. A significantly higher level of PTHrP
mRNA was expressed in smooth muscle tissue than in
urothelium (6.07 2.56-fold comparedwith urothelium;
P .046, Figure 2C). For assessing the putative target of
PTHrP in the bladder, we also examined the localization
of PTH1R,which is the only type of PTH/PTHrP receptor
targeted by PTHrP (11). In contrast with the dynamic
changes in PTHrP levels, the expression of the PTH1R
transcript remained relatively stable under bladder disten-
sion (Figure 2A). PTH1Rwas predominantly expressed in
smooth muscle both in mRNA level (4.43  0.28-fold
compared with urothelium; P 1.05 105, Figure 2C)
and in protein level (Figure 2D), suggesting that PTHrP is
likely to function on smooth muscle rather than on
urothelium.
Effect of PTHrP(1-34) treatment on intracellular
cAMP of BSMCs
Because PTH1R is predominantly localized in themus-
cle layer, we focused on the physiologic effects of PTHrP
Table 2. Result of Affymetrix Genechip array.
Fold
Change Gene Description Gene Symbol P Value
20.827 Activating transcription factor 3 Atf3 .023
18.166 Activity-regulated cytoskeleton-associated protein Arc .002
16.859 IL-6 Il6 .049
12.006 Chemokine (C-X-C motif) ligand 2 Cxcl2 .021
10.632 Hyaluronan synthase 1 Has1 .023
10.556 TNF receptor superfamily, member 12a Tnfrsf12a .001
9.701 Cysteine-rich, angiogenic inducer, 61 Cyr61 7  10–5
9.282 Serine (or cysteine) peptidase inhibitor, clade E, member 1 Serpine1 .012
8.859 OTU domain containing 1 Otud1 .026
8.686 Neuronal pentraxin 2 Nptx2 .0006
8.599 Regulator of calcineurin 1 Rcan1 .006
8.526 Xin actin-binding repeat containing 1 Xirp1 .045
8.226 Nuclear receptor subfamily 4, group A, member 1 Nr4a1 .006
7.866 Apolipoprotein L domain containing 1 Apold1 .009
7.815 Connective tissue growth factor Ctgf .003
7.683 CCR4 carbon catabolite repression 4-like (S. cerevisiae) Ccrn4l .035
7.251 Suppressor of cytokine signaling 3 Socs3 .047
7.057 Glutamine-fructose-6-phosphate transaminase 2 Gfpt2 .014
6.874 FBJ osteosarcoma oncogene Fos .001
6.645 Tribbles homolog 1 (Drosophila) Trib1 .012
6.582 Fos-like antigen 1 Fosl1 .038
6.167 PTH-like hormone ( PTHrP) Pthlh (Pthrp) .002
5.869 Epiregulin Ereg .075
5.834 Myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila); translocated to, 11
Mllt11 0.009
5.733 Similar to RIKEN cDNA 6330406I15 RGD1307396 .024
5.713 BTG family, member 2 Btg2 .006
5.567 Major facilitator superfamily domain containing 2 Mfsd2 .002
5.476 Nucleoporin 62 C-terminal like Nup62cl .001
5.435 Similar to 1300014I06Rik protein RGD1311307 .012
5.337 Poliovirus receptor PVR .002
The table is a list of top 30 genes highly up-regulated in distended bladder. Bold, 22nd highest up-regulation.
2062 Nishikawa et al PTHrP and Bladder Smooth Muscle Endocrinology, June 2013, 154(6):2058–2068
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 19:03 For personal use only. No other uses without permission. . All rights reserved.
peptide on bladder smooth muscle. In parallel with the
findings from the separated bladder tissues, BSMCs iso-
lated from rat bladders expressed significantly more
PTH1R than UC, both in mRNA level (Figure 3A-1), and
in protein level (Figure 3A-2). In smooth muscle of other
organs, PTHrP is known to act as a smooth muscle relax-
ant via the adenylyl cyclase (AC)-cAMP-protein kinase A
(PKA) pathway (24–26). Therefore,
we first investigated the effect of
PTHrPonthe intracellularcAMPcon-
centration of BSMCs.As expected, 10
nMPTHrP(1–34) treatment increased
the intracellular cAMPconcentration,
and this effect was significantly inhib-
ited by 10 nM PTHrP(7–34), a com-
petitive antagonist of PTHrP, and 10
M SQ22536, an adenylyl cyclase
(AC) inhibitor (Figure3B), confirming
that PTHrP increased intracellular
cAMP levels via PTH1R and AC.
Effect of PTHrP on spontaneous
contraction of bladder smooth
muscle
Although PTHrP was previously
reported to be a bladder muscle re-
laxant, its effect was only modest
when evaluated againstCch-induced
contraction (12, 13). Considering
the relevant relaxant effect of PTHrP
on other types of smooth muscle
(24), we hypothesized that the blad-
der PTHrP/PTH1R axis may prefer-
entially suppress spontaneous con-
traction not tested in previous
reports. Thus, we examined the ef-
fect of PTHrP on spontaneous con-
traction in rat bladder strips in organ
bath study.
Indeed, 10 nM PTHrP(1–34)
treatment potently suppressed the
spontaneous contraction amplitude
of the bladder detrusor muscle in a
dose-dependent manner (Figure 4, A
and C), but did not change the area
under the curve (Figure 4D) and the
intercontraction interval (Figure
4E). Compared to the effect on am-
plitude, the baseline decrease after
PTHrP(1–34) treatment was rela-
tively mild (Figure 4B).
PTHrP acts via the AC-cAMP-
PKA pathway in smooth muscle of
many organs including blood vessels, gall bladder, and tra-
chea (10, 24–26). Indeed, 8-bromo-cAMP, a cAMPanalog,
and forskolin, an AC activator, have inhibitory effect sim-
ilar to that of PTHrP (Supplemental Figure 1, A–C, pub-
lishedonTheEndocrineSociety’s JournalsOnlineweb site

























































































































Figure 2. Expression Profiles of PTHrP and PTH1R A, Up-regulation of PTHrP mRNA by bladder
distention was certified by real-time RT-PCR. The value of the empty group is set at 1 (n  4-5;
*P  .05). On the contrary, PTH1R mRNA did not change significantly with bladder distention.
SV, storing-voiding. B, PTHrP protein was up-regulated in the distended bladder. 1.
Representative immunoblot of 6 hours Empty group and 6 hours Distension group (n  2). 2.
Densitometry of immunoblot result from another independent experiment. Relative PTHrP
protein level was calculated from the PTHrP signal density adjusted by the signal density of -
actin (n  6; P .011). *P .05. C, Real-time RT-PCR showing localization of PTHrP and PTH1R
mRNA in the bladder (n  5). Expression levels of 3 smooth muscle markers (Calponin, smooth
muscle myosin heavy chain [SM-MHC], and -SMA) and 2 urothelial markers (uroplakin 3a
[UP3a] and cytokeratin 20 [CK20]) are shown as open bars. PTHrP and PTH1R protein mRNA
expression were both dominant in the smooth muscle layer (n  5; P  .046 and 1.0  105,
respectively; P  .05). D, Immunoblot showing that the PTH1R protein is predominantly
expressed in smooth muscle of the bladder. Separation of the smooth muscle layer and the
urothelial layer was validated by immunoblotting with -SMA and cytokeratin 18 antibodies. SM,
smooth muscle layer; U, urothelial layer.
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to explore the downstream pathway of PTH1R by phar-
macologic inhibition using the protein kinase A inhibitor
H89 (10 M) (27), or the AC inhibitor SQ22536 (300
M) (28). However, those inhibitors themselves sup-
pressed spontaneous contraction (Supplemental Figure
2A for H89; Supplemental Figure 2B for SQ22536), and
thus further inhibition study was not possible.
Effect of PTHrP on Cch-induced contraction of
bladder smooth muscle
The effects of PTHrP on Cch-induced contraction of
bladder smooth muscle were examined (12, 13). Consis-
tent with the inhibitory actions of PTHrP reported in pre-
vious studies, PTHrP(1–34) reduced a raised baseline in
bladder smooth muscle preparations that had been pre-
contracted with CCh (0.1 M) (Figure 5, A and B). How-
ever, the inhibition of CCh-induced
contraction was relatively mild
compared with the prominent effect
observed with spontaneous contrac-
tion. Other parameters, peak ampli-
tude, interval time, and area under
curve, were not changed signifi-
cantly (Figure 5, C–E). Thus, inhibi-
tion of spontaneous contraction was
considered to be a more relevant
physiologic function of PTHrP in
bladder smooth muscle than inhibi-
tion of contraction triggered by cho-
linergic stimulus.
Effect of PTHrP on
cystometrogram
Finally, we performed a rat cys-
tometrogram to investigate the in
vivo effect of PTHrP. Intravenous
administration of 10 g PTHrP(1-
34) rapidly induced a significant but
transient increase in bladder compli-
ance and a decrease in maximum in-
travesical pressure (Figure 6, A, B,
and D). The treatment did not affect
the voiding interval (Figure 6C) and
residual urine volume. These find-
ings demonstrate that PTHrP is a
physiologically relevant bladder re-
laxant in vivo.
Discussion
This report demonstrates that PTHrP is
up-regulated in the bladder under
distension, inhibits spontaneous contraction of detrusor
smoothmuscle expressing PTH1R, and alters compliance
and voiding contraction amplitude of the bladder. These
findings suggest physiologic significance of the PTHrP/
PTH1R axis in regulation of bladder function.
Bladder distension resulting from acute or chronic dif-
ficulty to void is a common urologic phenomenon. Me-
chanical stretch on smooth muscle (7, 29), as well as hyp-
oxia with hypoperfusion (4, 30) and other stressors, can
cause transcriptional changes that ultimately lead tomyo-
genic alterations in bladder function (5). We performed
comprehensive gene expression analysis in an in vivoblad-
der distentionmodel. Thismodel has potential advantages
over the in vitro system because it reflects all direct and
indirect factors affecting transcriptional changes in the
Figure 3. PTHrP and PTH1R Pathway Increases Intracellular cAMP through the AC-cAMP-PKA
Pathway A, BSMCs expressing PTH1R. A-1, Real-time RT-PCR showing that PTH1R expression is
more than 100-fold higher in BSMCs than in UCs in mRNA level. *P .05 against UC expression
set as 1. A-2, Immunoblot showing higher PTH1R expression in BSMCs than in UCs. B,
Intracellular cAMP increased by treatment with 10 nM PTHrP(1–34), which was inhibited by the
addition of 10 nM PTHrP(7-34), the antagonist peptide, and 10 M SQ22536, the adenyl cyclase
inhibitor. *P  .05, against the cells treated with PTHrP(1–34) alone. CK18, cytokeratin 18.
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bladder, ie, muscle stretch, altered innervation, hypoxia,
and hypoperfusion. In thismodelwe rediscovered PTHrP,
which has been reported in the literature as a stretch-in-
duced gene in BSMC, as one of the most up-regulated
genes by bladder distention (12, 13). Although a previous
BSMC microarray did not identify PTHrP as a stretch-
related gene (7), our review of the raw data of that mi-
croarray revealed that stretch did increase PTHrP, but one
outlier datum among the 3 samples
made the result statistically insignif-
icant. In comprehensive analysis
such as microarray important candi-
date molecules may be missed be-
cause of outlier data. Thus,multiple-
array analyses on multiple models,
likeBSMCinvitroandbladder tissue
in vivo, not only confirm the similar-
ity of the two systems, but also pro-
vide a chance to pick up important
candidate molecules missed by a sin-
gle model. The other possibility is
that, in addition to sheer stress itself,
ischemia with bladder distension
also up-regulated PTHrP (31, 32),
and that an in vivo system generated
a more distinct change in PTHrP ex-
pression than an in vitro stretch sys-
tem without hypoxia.
An important finding of this pa-
per is that PTH1R, the receptor of
PTHrP, is predominantly localized in detrusor smooth
muscle. This result and concurrent expressionof PTHrP in
detrusor smoothmuscle indicate thatPTHrPmay function
in an autocrine or paracrine fashion in smooth muscle.
Although a recent study using immunohistochemistry re-
ported that PTHrPwasup-regulated in theurothelial layer
of distended rabbit bladders (14), our results clearly show
that the target tissue for PTHrP is not
the urothelium because it expresses
very low levels of PTH1R, and blad-
der PTH1R level remains constant
under distension. Also, in the previ-
ous report, PTHrP up-regulation in
theurotheliumwasnot confirmedby
biochemical methods like RT-PCR
and immunoblotting, so that it could
not be determined whether the in-
crease in immunostaining signal was
specific to PTHrP.
According to our localization
study and the results from previous
papers, we postulated that the
PTHrP-PTH1R pathway may be a
detrusor smooth muscle relaxant in
the bladder. PTHrP acts via the AC-
cAMP-PKA pathway in smooth
muscle of many organs including
blood vessels, gall bladder, and tra-
chea (10, 24–26), and we confirmed


































Figure 5. The Effect of PTHrP(1-34) on Cch-Induced Contractions of Rat Bladder Muscle Strips
PTHrP(1-34) reduced the baseline increase of Cch-induced contractions in rat bladder detrusor
muscle strips but had no significant effect on other parameters, including peak amplitude (Amp),
area under curve, and interval time. Cch, carbachol treatment only; CchP, carbachol with























































Figure 4. The Effect of PTHrP(1-34) on Cch-Induced Contractions of Rat Bladder Muscle Strips
PTHrP(1-34) induced a moderate decrease in baseline tension and a marked decrease in peak
amplitude (Amp) in rat bladder detrusor muscle strips without significant change of the interval
time and area under curve, in a dose-dependent manner. *P  .05.
doi: 10.1210/en.2012-2142 endo.endojournals.org 2065
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 19:03 For personal use only. No other uses without permission. . All rights reserved.
tions under the same mechanism in vitro. Consistently,
8-bromo-cAMP, a cAMP analog, and forskolin, an AC
activator, have an inhibitory effect similar to that of
PTHrP (Supplemental Figure 1, A–C).However, we could
not confirm the involvement of AC-cAMP-PKA pathway
by inhibition study with H89, a PKA inhibitor (Supple-
mental Figure 2A), and SQ22536, an AC inhibitor (Sup-
plemental Figure 2B), because these inhibitors themselves
caused smooth muscle relaxation. The relaxant effect of
H89 could have been due to Rho-kinase inhibition as re-
ported previously (33). Although a muscle relaxant effect
of SQ22536 is not reported in the literature, the relaxant
effect of SQ22536 was reproducible in our experimental
system. In addition, SQ22536 had no significant effect on
relaxation of pulmonary vessels induced by PTHrP(1–34)
(34), and this result was interpreted to mean that the ac-
tion of SQ22536 may have varied with AC isoforms, and
that AC isoforms involved in tensionmodulationmay not
have been sensitive to SQ22536 (35). In short, although
the AC-cAMP-PKA pathway is likely to be the down-
stream pathway of PTH1R, it is not a definitive
conclusion.
Themost striking finding of this study is that PTHrP(1-
34) potently suppresses spontaneous bladder smooth
muscle contraction, while exerting only a modest inhibi-
tory effect on Cch-induced bladder
contraction as previously reported
(12, 13). Spontaneous bladder con-
traction has been shown to be a very
localized, asynchronous event in
normal rat bladders (36, 37), but it
becomes more synchronized with a
larger amplitude after spinal cord
transection (37) and bladder outlet
obstruction (38). Such spontaneous
contraction evokes afferentnerve fir-
ing in mouse bladders with detrusor
overactivity (39) and may underlie
abnormal increases in intravesical
pressure (40).The sensitizationof af-
ferent fibers and/or increase in the
magnitude of spontaneous contrac-
tion has been implicated in a number
of bladder pathologies (41). Various
inhibitory agents of spontaneous
contraction have been reported to
target -adrenoceptor, Rho-kinase,
intracellular calcium, and cAMP
(42–45). Stretch-activated potas-
sium channelsmay act as an intrinsic
mechanism for suppressing bladder
smooth muscle excitability (46).
However, to our knowledge, an endogenous inhibitory
ligand/receptor pair has not yet been established for spon-
taneous contraction, making our findings unique in the
literature.
Another intriguing finding in this study is the effect of
PTHrP(1–34) on cystometrogram change. It caused a
rapid and temporal increase in bladder compliance and a
decrease in maximum intravesical pressure. Although
spontaneous contraction does not contribute to a phasic
rise in the intravesical pressure of normal bladders (36),
suppression of spontaneous contraction could be associ-
ated with increased bladder compliance. However, we
should be cautious in interpreting all the observed cys-
tometrogram changes as myogenic, because systemically
administered PTHrP might work on other sites of the
body, including nerves and sphincters. Thus, further stud-
ies may be needed to define precise links between PTHrP-
mediated inhibition of spontaneous bladder contraction
and in vivo bladder phenomenology.
Muscle remodeling in acute or chronic bladder outlet
obstruction is often associated with detrusor overactivity,
with increased muscle excitability and contractility (2, 4).
PTHrP may counterbalance and alleviate the increased
muscle contractility to avoid cell injury caused by exces-












































































Figure 6. Cystometrogram Showing the in Vivo Effect of iv PTHrP(1-34) Administration A,
Cystometrogram around iv administration of saline or 10g PTHrP(1-34) amide. A typical trace of
a rat is shown. B, PTHrP(1-34) decreased maximum intravesical pressure (max. Pves). The graph
shows the relative change after 10 g PTHrP(1-34) administration (n  7-10). C, PTHrP(1-34) did
not affect the voiding interval. The graph shows the relative change after 10 g PTHrP
administration (n  7-10; P  .092). D, PTHrP(1-34) increased bladder compliance. Open bars
show the compliance before administration, solid bars the compliance after administration (n 
7-10; P  .396 [saline], P  .030 [PTPrP(1-34] treatment). Mean value of the data before
administration set at 1 for (B) and (C). max. Pves, maximum intravesical pressure. *P  .05.
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of the PTHrP/PTH1R axis could be postulated as a ther-
apeuticmeasure for treating pathologic conditions such as
detrusor overactivity or low compliance bladders, the det-
rimental consequences of bladder outlet obstruction. Al-
though PTHrP did not change the voiding interval and
only subtly increased bladder compliance in healthy ani-
mals in our study, it could be expected that PTHrP, or its
bladder-specific agonist, could be a therapeutic agent for
pathologic conditions associated with detrusor overactiv-
ity, which should be investigated in further studies.
In conclusion, PTHrP acts as a unique endogenous
relaxant of detrusor smooth muscle, preferentially in-
hibiting spontaneous contraction while suppressing
cholinergic contraction to a lesser extent, and thus the
PTHrP-PTH1R system may be a novel target for treat-
ing detrusor overactivity.
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